Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma Journal Article
| Author: | Meyers, P. A. |
| Article Title: | Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma |
| Abstract: | The recruitment of autologous macrophages to attack osteosarcoma represents a novel immunotherapy approach to the treatment of osteosarcoma. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) was derived as a compound with the ability to stimulate macrophages to destroy autologous osteosarcoma tumor cells. Preclinical studies including studies in dogs with spontaneously arising osteosarcoma showed the ability of L-MTP-PE to control microscopic metastatic disease in osteosarcoma. A pivotal clinical trial led to the approval of L-MTP-PE for the treatment of newly diagnosed osteosarcoma in over 40 countries. © 2020, Springer Nature Switzerland AG. |
| Keywords: | osteosarcoma; cancer chemotherapy; treatment outcome; survival rate; unclassified drug; cancer growth; drug efficacy; nonhuman; adjuvant therapy; recurrence risk; antineoplastic agent; drug effect; immunotherapy; drug response; clinical effectiveness; muramyl tripeptide; macrophages; randomized controlled trial (topic); cancer prognosis; human; priority journal; muramyl tripeptide phosphatidyl ethanolamine encapsulated in liposome |
| Journal Title: | Advances in Experimental Medicine and Biology |
| Volume: | 1257 |
| ISSN: | 0065-2598 |
| Publisher: | Springer |
| Date Published: | 2020-01-01 |
| Start Page: | 133 |
| End Page: | 139 |
| Language: | English |
| DOI: | 10.1007/978-3-030-43032-0_11 |
| PUBMED: | 32483736 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter 11 in Kleinerman E, Gorlick R, eds. Current Advances in Osteosarcoma: Clinical Perspectives: Past, Present and Future, 2nd ed. (ISBN: 978-3-030-43031-3) -- Export Date: 1 July 2020 -- Source: Scopus |
